Analysts at ROTH Capital downgraded Verastem, Inc. (VSTM) from ‘Buy’ to ‘Neutral’ in a research report issued to clients on Monday. The target price for VSTM is lowered from $23 to $2. The 91% cut came after the biopharmaceutical company halted the study of its experimental cancer therapy after studies showed that the treatment was […]
View the full post at: Notable Downgrades: Verastem (VSTM), TD Ameritrade (AMTD), SanDisk (SNDK), Micron (MU), BlackBerry (BBRY)